Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has reported that the first patient has been enrolled in its Proency, ENdeavor and CYpher European registry. The registry is the first to observe different 'Olimus'-eluting coronary stents.
Subscribe to our email newsletter
The registry will enroll up to 2,500 patients with simple and complex lesions at multiple sites in several European countries. Of the patients at each site, half will receive the Promus Stent and half will receive either the Cypher or the Endeavor Stent to attain a 2:1:1 ratio of Promus, Cypher, and Endeavor Stents respectively. The primary endpoint of the registry will be the rate of major cardiac events (cardiac death, all myocardial infarction and target vessel revascularization) at 12 months.
The registry will collect real-life clinical outcome data for Boston Scientific’s Promus Everolimus-Eluting Coronary Stent and compare them with data from Johnson & Johnson’s Cypher Sirolimus-Eluting Stent and Medtronic’s Endeavor Zotarolimus-Eluting Stent in patients in routine clinical practice. The Promus Stent is a private-labeled Xience Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific.